Literature DB >> 17337774

Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines.

Pawel Kalinski1, Yutaro Nakamura, Payal Watchmaker, Adam Giermasz, Ravikumar Muthuswamy, Robbie B Mailliard.   

Abstract

The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8+ and CD4+ T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8+ T cells and NK cells, the classical "effector" cells, also play "helper" roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8+ T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17337774     DOI: 10.1385/IR:36:1:137

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  69 in total

Review 1.  How dendritic cells and microbes interact to elicit or subvert protective immune responses.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Curr Opin Immunol       Date:  2002-08       Impact factor: 7.486

2.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.

Authors:  Todd A Fehniger; Megan A Cooper; Gerard J Nuovo; Marina Cella; Fabio Facchetti; Marco Colonna; Michael A Caligiuri
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

3.  Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.

Authors:  N C Fernandez; A Lozier; C Flament; P Ricciardi-Castagnoli; D Bellet; M Suter; M Perricaudet; T Tursz; E Maraskovsky; L Zitvogel
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

4.  Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.

Authors:  Ryuya Yamanaka; Susan A Zullo; Jay Ramsey; Naoki Yajima; Naoto Tsuchiya; Ryuichi Tanaka; Michael Blaese; Kleanthis G Xanthopoulos
Journal:  J Neurosurg       Date:  2002-09       Impact factor: 5.115

Review 5.  Tumor-host immune interactions and dendritic cell dysfunction.

Authors:  Li Yang; David P Carbone
Journal:  Adv Cancer Res       Date:  2004       Impact factor: 6.242

6.  Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells.

Authors:  J Rodrigo Mora; Maria Rosa Bono; N Manjunath; Wolfgang Weninger; Lois L Cavanagh; Mario Rosemblatt; Ulrich H Von Andrian
Journal:  Nature       Date:  2003-07-03       Impact factor: 49.962

7.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets.

Authors:  Thomas Luft; Michael Jefford; Petra Luetjens; Tracey Toy; Hubertus Hochrein; Kelly-Anne Masterman; Charlie Maliszewski; Ken Shortman; Jonathan Cebon; Eugene Maraskovsky
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.

Authors:  Yuji Satoh; Clemens Esche; Andrea Gambotto; Galina V Shurin; Zoya R Yurkovetsky; Paul D Robbins; Simon C Watkins; Satoru Todo; Ronald B Herberman; Michael T Lotze; Michael R Shurin
Journal:  J Exp Ther Oncol       Date:  2002 Nov-Dec

Review 9.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

10.  Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.

Authors:  Robbie B Mailliard; Young-Ik Son; Richard Redlinger; Patrick T Coates; Adam Giermasz; Penelope A Morel; Walter J Storkus; Pawel Kalinski
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.426

View more
  31 in total

Review 1.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

2.  In vitro immunogenic and immunostimulatory effects of zwitterionized 23-valent pneumococcal polysaccharide vaccine compared with nonzwitterionized vaccine.

Authors:  Ahmed S Abdulamir; Rand R Hafidh; Fatimah Abubaker
Journal:  Curr Ther Res Clin Exp       Date:  2010-02

Review 3.  Dendritic cell interactions with NK cells from different tissues.

Authors:  Guido Ferlazzo; Christian Münz
Journal:  J Clin Immunol       Date:  2009-03-12       Impact factor: 8.317

4.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.

Authors:  Shuko Murakami; Yasumitsu Nishimura; Megumi Maeda; Naoko Kumagai; Hiroaki Hayashi; Ying Chen; Masayasu Kusaka; Takumi Kishimoto; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2009-03-18       Impact factor: 3.674

5.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Authors:  Pawel Kalinski; Howard Edington; Herbert J Zeh; Hideho Okada; Lisa H Butterfield; John M Kirkwood; David L Bartlett
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 6.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 7.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

Review 8.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

9.  A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; William Depas; Sergey S Seregin; Chyong-Jy J Liu; Nathan Schuldt; Darin Quach; Dionisia Quiroga; Sarah Godbehere; Igor Zlatkin; Sungjin Kim; J Justin McCormick; Andrea Amalfitano
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

Review 10.  Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.

Authors:  Pawel Kalinski; Julie Urban; Rahul Narang; Erik Berk; Ewa Wieckowski; Ravikumar Muthuswamy
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.